Theralase Technologies Valuation
| TLTFF Stock | USD 0.19 0.01 5.00% |
Theralase Technologies seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Theralase Technologies from inspecting the company fundamentals such as Return On Equity of -1.13, shares owned by insiders of 2.56 %, and Current Valuation of 51.77 M as well as reviewing its technical indicators and probability of bankruptcy. . In general, most investors recommend locking in undervalued stocks and disposing overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
Overvalued
Today
Please note that Theralase Technologies' price fluctuation is out of control at this time. Calculation of the real value of Theralase Technologies is based on 3 months time horizon. Increasing Theralase Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Theralase otc stock is determined by what a typical buyer is willing to pay for full or partial control of Theralase Technologies. Since Theralase Technologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Theralase OTC Stock. However, Theralase Technologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.19 | Real 0.17 | Hype 0.19 |
The real value of Theralase OTC Stock, also known as its intrinsic value, is the underlying worth of Theralase Technologies OTC Stock, which is reflected in its stock price. It is based on Theralase Technologies' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Theralase Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Theralase Technologies helps investors to forecast how Theralase otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Theralase Technologies more accurately as focusing exclusively on Theralase Technologies' fundamentals will not take into account other important factors: Theralase Technologies Total Value Analysis
Theralase Technologies is at this time forecasted to have takeover price of 51.77 M with market capitalization of 61.59 M, debt of 494.32 K, and cash on hands of 1.46 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Theralase Technologies fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
51.77 M | 61.59 M | 494.32 K | 1.46 M |
Theralase Technologies Investor Information
The company recorded a loss per share of 0.02. Theralase Technologies had not issued any dividends in recent years. Based on the key indicators related to Theralase Technologies' liquidity, profitability, solvency, and operating efficiency, Theralase Technologies is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Theralase Technologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Theralase Technologies has an asset utilization ratio of 13.13 percent. This implies that the OTC Stock is making $0.13 for each dollar of assets. An increasing asset utilization means that Theralase Technologies is more efficient with each dollar of assets it utilizes for everyday operations.Theralase Technologies Ownership Allocation
Theralase Technologies shows a total of 216.5 Million outstanding shares. About 97.44 % of Theralase Technologies outstanding shares are held by general public with 2.56 (%) owned by insiders and only 0.0 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Theralase Technologies Profitability Analysis
The company reported the revenue of 780.64 K. Net Loss for the year was (4.41 M) with profit before overhead, payroll, taxes, and interest of 278.88 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Theralase Technologies' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Theralase Technologies and how it compares across the competition.
About Theralase Technologies Valuation
The otc valuation mechanism determines Theralase Technologies' current worth on a weekly basis. Our valuation model uses a comparative analysis of Theralase Technologies. We calculate exposure to Theralase Technologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Theralase Technologies's related companies.Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada. Theralase Technologi operates under Medical Devices classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Theralase Technologies' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Theralase Technologies' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Theralase Technologies' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Theralase Technologies' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Theralase Technologies' revenue streams: Identify Theralase Technologies' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Theralase Technologies' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Theralase Technologies' growth potential: Evaluate Theralase Technologies' management, business model, and growth potential.
- Determine Theralase Technologies' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Theralase Technologies' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Theralase Technologies Growth Indicators
Investing in growth stocks can be very risky. If the company such as Theralase Technologies does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 204.3 M | |
| Retained Earnings | -53.1 M |
Complementary Tools for Theralase OTC Stock analysis
When running Theralase Technologies' price analysis, check to measure Theralase Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theralase Technologies is operating at the current time. Most of Theralase Technologies' value examination focuses on studying past and present price action to predict the probability of Theralase Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theralase Technologies' price. Additionally, you may evaluate how the addition of Theralase Technologies to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |